Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination

Vaccine
Céline VerheustDidier Breyer

Abstract

The modified vaccinia virus Ankara (MVA) strain is a highly attenuated strain of vaccinia virus that has been demonstrated to be safe for humans. MVA is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile. It also represents an excellent candidate for use as vector system in recombinant vaccine development for gene delivery or vaccination against infectious diseases or tumours, even in immunocompromised individuals. The use of MVA and recombinant MVA vectors must comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The purpose of the present paper is to highlight some biological characteristics of MVA and MVA-based recombinant vectors and to discuss these from a biosafety point of view in the context of the European regulatory framework for genetically modified organisms with emphasis on the assessment of potential risks associated with environmental release.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·G Sutter, B Moss
Jan 1, 1989·Archives of Virology·W AltenburgerJ Altenburger
Jul 4, 2001·Journal of Virology·X D Yao, D H Evans
Jun 24, 2003·Comparative Immunology, Microbiology and Infectious Diseases·P-P Pastoret, A Vanderplasschen
Oct 11, 2003·The Journal of Infectious Diseases·Vasee S MoorthyAdrian V S Hill
Feb 6, 2004·Expert Review of Vaccines·Michael J Corbel, Dorothy K L Xing
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Massimo Di NicolaAndrea Anichini
Nov 25, 2004·Current Opinion in Biotechnology·Ingo DrexlerGerd Sutter
Sep 6, 2005·Traffic·Birgit Schramm, Jacomine Krijnse Locker
Sep 15, 2005·Vaccine·Alexandra TimmPaul Chaplin
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard HarropMiles W Carroll
Dec 13, 2006·The Journal of Allergy and Clinical Immunology·Janie Parrino, Barney S Graham
Aug 19, 2007·The Journal of General Virology·Carmen Elena GómezMariano Esteban
Sep 21, 2007·The Journal of Gene Medicine·Ellen A M Schenk-BraatLeonie C M Kaptein
Nov 21, 2007·The Journal of General Virology·Christine Meisinger-HenschelJürgen Hausmann

❮ Previous
Next ❯

Citations

Dec 21, 2012·Animal Health Research Reviews·Qi ChenD L Hank Harris
Dec 8, 2015·Expert Review of Vaccines·Fang HeJimmy Kwang
Oct 31, 2013·Expert Review of Vaccines·Carmen Elena GómezMariano Esteban
Oct 13, 2015·Expert Opinion on Investigational Drugs·Lynne HampsonIan N Hampson
Nov 1, 2015·Virus Research·Mercedes Fernández-EscobarSusana Guerra
Aug 17, 2012·Human Vaccines & Immunotherapeutics·Houda BoukhebzaGeneviève Inchauspé
May 27, 2014·Frontiers in Immunology·Rudra Chhajer, Nahid Ali
Jan 25, 2018·Current Protocols in Human Genetics·Scott Swindle
Mar 18, 2020·Proceedings of the National Academy of Sciences of the United States of America·Gerd Sutter
Dec 4, 2019·Expert Review of Vaccines·Iván Del Moral-Sánchez, Kwinten Sliepen
Oct 21, 2020·Vaccine·Ariane VolkmannUNKNOWN Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG
Aug 15, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jessica WingerathThomas C Wirth

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. Discover the latest research on acute disseminated encephalomyelitis here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.